- Home
- DYAI vs MLCI Comparison
DYAI vs MLCI Comparison
Compare DYAI & MLCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DYAI | MLCI |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 33.7M |
| IPO Year | 2026 | 2026 |
Fundamental Metrics
Financial Performance| Metric | DYAI | MLCI |
|---|---|---|
| Price | $0.43 | $3.24 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 142.2K | 14.8K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,090,345.00 | ★ $53,566,000.00 |
| Revenue This Year | $122.79 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.58 |
| 52 Week Low | $0.46 | $2.56 |
| 52 Week High | $1.60 | $8.68 |
Technical Indicators
Market Signals| Indicator | DYAI | MLCI |
|---|---|---|
| Relative Strength Index (RSI) | 20.09 | 52.32 |
| Support Level | N/A | $3.15 |
| Resistance Level | $0.90 | $3.30 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 15.66 | 65.00 |
Price Performance
Historical ComparisonAbout DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About MLCI Mount Logan Capital Inc.
Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The company's reporting segments include asset management and insurance. The company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The Asset Management segment comprises all fee generating activities. The Insurance Solutions segment, which derives maximum revenue, consists of two product lines within the insurance business, LTC and MYGA.